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RESEARCH ARTICLE
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Abstract
Bacterial invasion of synovial joints, as in infectious or septic arthritis, can be difficult to treat
in both veterinary and human clinical practice. Biofilms, in the form of free-floating clumps or
aggregates, are involved with the pathogenesis of infectious arthritis and periprosthetic joint
infection (PJI). Infection of a joint containing an orthopedic implant can additionally compli-
cate these infections due to the presence of adherent biofilms. Because of these biofilm
phenotypes, bacteria within these infected joints show increased antimicrobial tolerance
even at high antibiotic concentrations. To date, animal models of PJI or infectious arthritis
have been limited to small animals such as rodents or rabbits. Small animal models, how-
ever, yield limited quantities of synovial fluid making them impractical for in vitro research.
Herein, we describe the use of ex vivo equine and porcine models for the study of synovial
fluid induced biofilm aggregate formation and antimicrobial tolerance. We observed Staphy-
lococcus aureus and other bacterial pathogens adapt the same biofilm aggregate pheno-
type with significant antimicrobial tolerance in both equine and porcine synovial fluid,
analogous to human synovial fluid. We also demonstrate that enzymatic dispersal of syno-
vial fluid aggregates restores the activity of antimicrobials. Future studies investigating the
interaction of bacterial cell surface proteins with host synovial fluid proteins can be readily
carried out in equine or porcine ex vivo models to identify novel drug targets for treatment of
prevention of these difficult to treat infectious diseases.
Introduction
Infectious or septic arthritis is an orthopedic emergency that results in substantial morbidity
and mortality[1–3]. Staphylococcus aureus (S. aureus) is the most common bacterial organism
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isolated from infectious arthritis and also in periprosthetic joint infection (PJI), accounting for
the highest treatment failure rates[2,4–7]. These high treatment failure rates are linked to the
ability of Staphylococci to form robust biofilms[7–10]. The traditional definition of a biofilm is
a community of bacteria within a polymeric matrix that is attached to an abiotic or biotic sur-
face[11]. However, recent advancements in biofilm research suggests that bacteria do not need
a surface for formation; rather bacteria may attach to one another or host-derived proteins to
form a biofilm[12–16].
Current work in the infectious arthritis field has shown the ability of S. aureus to form free-
floating biofilms in human synovial fluid both in vitro and in vivo[17–20]. Within that body of
work, the authors evaluated both S. aureus laboratory strains and clinical isolates from human
patients [17]. In addition, biofilm aggregates have been described in other locations within the
body such as the lungs of cystic fibrosis (CF) patients, the middle ear, and on the skin
[12,14,21,22]. These biofilm aggregates displayed antimicrobial tolerance to cefazolin and vanco-
mycin in vitro[17–19]. The antimicrobial tolerance displayed by synovial fluid biofilm aggregates
is similar to traditional biofilms and the biofilm aggregates that form the sputum of CF patients
[13,23,24]. Continued in vitro investigations are critical for understanding this novel, free-float-
ing bacterial phenotype in synovial fluid; however, these research efforts can be hampered as
they rely on large volumes of synovial fluid which are difficult to source. Moreover, synovial
fluid from human donors can be of variable quality due to underlying donor pathology.
To date, rodent and rabbit models have been at the forefront of infectious arthritis and PJI
in vivo research[25,26]. However, rodent and rabbit cartilage biology as well as inflammatory
responses are significantly different from those of humans[27–30]. Moreover, synovial fluid is
difficult to obtain in large quantities from these species[31,32].
Large animals such as horses, pigs, goats, sheep and dogs have been successfully used to
explore mechanisms of non-infectious joint disease, particularly osteoarthritis[33–35]. The
advantage of large animal models is that their cartilage biology is more similar to that of
humans than rodents and rabbits[33,36–38] and substantially larger volumes of synovial fluid
can be collected. Of all the large animal models, horses and pigs are most commonly used for
the study of osteoarthritis because cartilage thickness and response to injury, as well as their
overall immune response, is similar to that of humans [33,35,39–41].
The objective of this study was to investigate if equine and porcine synovial fluid can be
used as an ex vivo model system of human joint infection and to investigate how microbial-
synovial fluid interactions limit antimicrobial activity. To achieve this goal, we first investi-
gated whether synovial fluid induced aggregate formation would occur across the aforemen-
tioned species. Next, we asked if biofilm aggregate formation would also be observed with
non-Staphylococcal species, i.e. Escherichia coli (E. coli), Streptococcus equi subspecies zooepi-
demicus (S. zooepidemicus) and Pseudomonas aeruginosa (P. aeruginosa). We then determined
if biofilm aggregate formation in synovial fluid leads to antimicrobial tolerance as a function
of antimicrobial class, bacterial species and synovial fluid source. Finally, we asked if enzymatic
dispersal of biofilm aggregates could restore antimicrobial activity.
Results
Staphylococcus aureus forms free-floating biofilm aggregates in equine,
human and porcine synovial fluid
When grown in human or bovine synovial fluid, S. aureus or S. epidermidis, respectively,
formed free-floating biofilm aggregates[17,20]. We first ascertained if S. aureus could form
biofilm aggregates in equine and porcine synovial fluid with similar structure to those formed
in human synovial fluid. Upon incubation of synovial fluid with S. aureus, aggregation was
Equine and porcine ex vivo models of human synovial fluid biofilms
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macroscopically evident within ~ 1–2 hours post-infection and biofilm aggregate size reached
a plateau at ~16–18 hours post infection (S1 Fig). We found that S. aureus formed biofilm
aggregates in all species by 24 hours post-infection (Fig 1A). Analysis using scanning electron
microscopy (SEM) indicated that biofilm aggregates had similar ultrastructure in equine, por-
cine and human synovial fluid. In each species, we observed S. aureus contained within a poly-
meric, cord-like, extracellular matrix (Fig 1B). Using confocal microscopy three-dimensional
(3D) reconstruction, we observed that synovial fluid biofilm aggregates exhibited a mixed pro-
tein (red, SYPRO) and carbohydrate (blue, WGA) extracellular matrix; nucleic acid/bacterial
staining (green, SYTO9) was scattered throughout the aggregate in all three species (Fig 1C).
Non-Staphylococcal arthrotropic bacteria form biofilm aggregates in
equine synovial fluid
Dastgheyb et al.[17] observed that methicillin-resistant (MRSA) and methicillin-sensitive S.
aureus, from both laboratory-adapted strains and clinical isolates from cases of human septic
arthritis, formed biofilm aggregates in synovial fluid. Therefore, we next asked if the biofilm
aggregate phenotype that develops in synovial fluid was restricted to S. aureus. Using arthro-
tropic clinical isolates derived from equine septic arthritis cases, we infected synovial fluid
with S. aureus, S. zooepidemicus, E. coli, or P. aeruginosa. These strains represent the most
Fig 1. Staphylococcus aureus forms macroscopic biofilm aggregates in the synovial fluid of several different
species. Equine, human or porcine synovial fluid was infected at 1x106 CFU/mL with S. aureus (ATCC25923) and
incubated overnight at 37˚C in a microaerophilic chamber on a shaker at 120rpm to mimic the joint environment. (A)
Macroscopic biofilm aggregates were observed in synovial fluid in all three species and photographed. (B) Aggregates
were removed from the synovial fluid, fixed, dehydrated in ethanol, sputter coated and imaged with a scanning
electron microscope with a FEI-Tecnai T12 microscope showing bacteria nested within a polymeric cord-like
extracellular matrix. (C) Aggregates were stained with wheat germ agglutinin (WGA (blue)) for carbohydrates, SYTO9
for nucleic acids/bacteria (green), and SYPRO (red) for proteinaceous content. Confocal laser scanning microscopy
(CLSM) was performed using a 12.5x upright lens on a Leica SP5 Multiphoton Microscope. CLSM images were
generated as 3-D reconstructions by sequential Z-stacking and tile scanning with Velocity software.
https://doi.org/10.1371/journal.pone.0221012.g001
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common isolates from equine infectious arthritis cases seen at the University of Pennsylvania
George D. Widener Hospital Large Animal Hospital in the last five years[42]. By 24 hours, S.
aureus formed large biofilm aggregates; S. zooepidemicus, E. coli, and P. aeruginosa also formed
aggregates in synovial fluid, although the aggregates were smaller than those formed with S.
aureus (Fig 2A). Micrograph analysis revealed that all biofilm aggregates were comprised of a
polymeric, cord-like, extracellular matrix heavily colonized by bacteria whose morphology and
size was consistent with bacterial strain (Fig 2B). Confocal microscopy 3D renderings of bio-
film aggregates showed similarities between all isolates (compare Fig 2C to Fig 1C).
Synovial fluid biofilm aggregates display antimicrobial tolerance to several
classes of drugs
We asked whether antimicrobial activity of several classes of antimicrobials against S. aureus
would be altered when cultured in equine synovial fluid (MIC concentrations presented in
Table 1). For all antimicrobials, planktonic bacteria in tryptic soy broth (TSB) were inhibited
or killed at 100× MIC (S2 Fig). In equine synovial fluid, S. aureus biofilm aggregates persisted
in vitro at 100× MIC (Fig 3A). Specifically, amikacin (an aminoglycoside), doxycycline (a tetra-
cycline), and vancomycin (a glycopeptide) reduced S. aureus bacterial concentration by >2 log
Fig 2. Gram-positive and gram-negative arthrotropic clinical isolates form macroscopic biofilm aggregates in
equine synovial fluid. Equine synovial fluid was infected at 1x106 CFU/mL for each clinical isolate (S. aureus, S.
zooepidemicus, E. coli, and P. aeruginosa) and incubated overnight at 37˚C in a microaerophilic chamber on a shaker at
120rpm to mimic the joint environment. (A) Macroscopic bacterial aggregates were observed in synovial fluid for all
four strains and photographed. (B) Aggregates visualized by SEM as in Fig 1. (C) Aggregates visualized by confocal
microscopy using WGA, Syto9 and SYPRO as in Fig 1.
https://doi.org/10.1371/journal.pone.0221012.g002
Equine and porcine ex vivo models of human synovial fluid biofilms
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Table 1. Median minimum inhibitory concentration of clinical isolates and ATCC25923 measured by antimicrobial susceptibility testing using the Sensititre Com-
plete Automated AST System and the equine (Equine EQUIN1F Vet AST Plate) antimicrobial susceptibility panel.
Antimicrobial Range S. aureus (ATCC
25923)
S. aureus S. zooepidemicus E. coli P. aeruginosa
Amikacin 4–32 � 4 � 4 8 � 4 � 4
Ampicillin 0.25–32 0.5 � 0.25 � 0.25 4 � 32
Azithromycin 0.25–4 0.5 � 0.25 � 0.25 2 � 4
Cefazolin 4–16 � 4 � 4 � 4 1 1
Ceftazidime 1–64 8 2 � 1 16 8
Ceftiofur 0.25–4 0.5 0.5 � 0.25 0.5 4
Chloramphenicol 4–32 8 � 4 � 4 8 � 32
Clarithromycin 1–8 � 1 � 1 � 1 8 � 8
Doxycycline 2–16 � 2 � 2 � 2 � 2 � 16
Enrofloxacin 0.25–2 � 0.25 � 0.25 1 � 0.25 1
Erythromycin 0.25–8 0.5 � 0.25 � 0.25 8 � 8
Gentamicin 1–8 � 1 � 1 � 1 � 1 2
Imipenem 1–8 � 1 � 1 � 1 � 1 1
Oxacillin+2% NaCl 0.25–4 � 0.25 � 0.25 � 0.25 � 4 � 4
Penicillin 0.06–8 � 0.06 � 0.06 � 0.06 � 8 � 8
Rifampin 1–4 � 1 � 1 � 1 � 4 � 4
Tetracycline 2–8 � 2 � 2 8 4 � 8
Ticarcillin 8–64 � 8 � 8 � 8 16 16
Ticarcillin-clavulanate 8/2-64/2 � 8/2 � 8/2 � 8/2 � 8/2 16/2
Trimethoprim Sulfa 0.5/9.5-4/76 1/19 � 0.5/9.5 � 0.5/9.5 � 0.5/9.5 4/76
https://doi.org/10.1371/journal.pone.0221012.t001
Fig 3. Synovial fluid biofilm aggregates show antimicrobial tolerance against several different classes of
antimicrobials. (A) S. aureus (ATCC25923) biofilm aggregates were allowed to form in equine synovial fluid for 6
hours and this aggregate-containing synovial fluid was treated with a panel of different antimicrobials from several
drug classes at 100× the minimum inhibitory concentration (MIC) as determined by in vitro antimicrobial
susceptibility testing (Table 1). No concentration of any antimicrobial evaluated in this experiment was able to
completely kill S. aureus grown in synovial fluid. (B) The four arthrotropic bacterial isolates from Fig 2 were grown in
equine synovial fluid or in tryptic soy broth (TSB). Synovial fluid or TSB was subsequently challenged with 1×, 10× or
100× MIC amikacin, an antibiotic with broad spectrum activity; these isolates were susceptible to amikacin based on
our in vitro antimicrobial susceptibility data. (C-E) S. aureus (ATCC25923) were incubated in equine, human or
porcine synovial fluid and this bacterial aggregate-containing synovial fluid was subsequently treated with amikacin
(C), doxycycline (D) or vancomycin (E) at 1×, 10× or 100× MIC. Bars are means and standard deviations of four
biological replicates (i.e. synovial fluid from four individual horses, humans or pigs; n = 4), and significant differences
(p<0.05) as determined by ANOVA with Tukey post-hoc are indicated by differing letters.
https://doi.org/10.1371/journal.pone.0221012.g003
Equine and porcine ex vivo models of human synovial fluid biofilms
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CFU/mL in equine synovial fluid (p<0.008; Fig 3A). As all four clinical isolates were suscepti-
ble to amikacin (based on antimicrobial susceptibility testing (Table 1)), we then used amika-
cin at 1×, 10× and 100× MIC to screen antimicrobial activity against biofilm aggregates in
synovial fluid formed by these isolates. S. zooepidemicus, E. coli, and P. aeruginosa were also
killed by amikacin at 1× MIC when grown in TSB planktonically (p<0.0001; Fig 3B). Little to
no killing was seen when the drug was used at 1× or 10× MIC against aggregate-containing
synovial fluid (Fig 3B); at 100× MIC, a modest decrease in bacterial concentration (~2–3 log
CFU/mL) was observed (p<0.009; Fig 3B). Similarly, these bacteria in synovial fluid from
equine, human and porcine sources were tolerant to amikacin (Fig 3C), doxycycline (Fig 3D)
and vancomycin (Fig 3E) at 1×, 10× and 100× MIC.
Enzymatic targeting of the proteinaceous matrix disperses synovial fluid
biofilm aggregates
Since confocal microscopy showed that synovial fluid biofilm aggregates display a mixed sugar
and protein matrix (Figs 1C and 2C) we tested the ability of different enzymes to hydrolyze the
synovial fluid biofilm aggregate matrix, disperse the bacteria and improve antimicrobial activ-
ity. After S. aureus aggregate formation in synovial fluid, enzymes including DNase, Disper-
sinB and proteinaseK, among others, were added to infected synovial fluid to target key
molecules within the aggregate extracellular matrix. In agreement with Dastgheyb et al.[17],
we showed that DispersinB and DNase did not disperse, while proteinaseK was able to
completely disperse, S. aureus biofilm aggregates in synovial fluid (p<0.004; Fig 4A and 4B).
Similar to Ibberson et al.[43], pre-treatment of synovial fluid with hyaluronidase, an enzyme
that targets hyaluronic acid, the main carbohydrate in synovial fluid, prevented aggregate
formation (S3A and S3B Fig); nevertheless, post-treatment with hyaluronidase only mildly
dispersed biofilm aggregates in synovial fluid (p<0.02; Fig 4A and 4B). In addition, the
proteolytic enzymes trypsin, endopeptidase (LysC), collagenase (type II), and dispase were
also able to moderately disperse aggregates in synovial fluid (p<0.001; Fig 4A and 4B). Finally,
collagenase (type IV), acetylcysteine and tissue plasminogen activator (TPA) were similar to
proteinaseK in that they significantly dispersed aggregates in synovial fluid (p<0.0001; Fig 4A
and 4B).
Enzymatic dispersal of synovial fluid biofilm aggregates restores
antimicrobial activity
Several studies have reported that dispersal of biofilms restores the activity of several classes of
antimicrobials[18,44–46]. To determine if dispersal of S. aureus biofilm aggregates restores
antimicrobial activity, synovial fluid containing bacterial aggregates was treated with each
enzyme for 1 hour, prior to challenge with amikacin at 10× MIC. Bacterial concentration (log
CFU/mL) was measured by serial dilutions and plate counting 8 hours post-antimicrobial
challenge. Control wells with enzymes alone did not alter bacterial concentration more than 1
log CFU/mL compared to untreated synovial fluid (S4 Fig). Trypsin, endopeptidase (LysC),
collagenase (type II) and dispase treatment prior to challenge with amikacin moderately
increased antimicrobial killing when compared to synovial fluid (containing aggregates) not
treated with enzymes (p<0.01; Fig 4C). ProteinaseK, collagenase (type IV), acetylcysteine and
TPA treatment prior to challenge with amikacin markedly increased antimicrobial activity as
compared to biofilm aggregates in synovial fluid not treated with enzymes (p<0.0003; Fig 4C).
Pre-treatment with hyaluronidase mildly increased antimicrobial killing (p<0.04) while no
change was observed with DNase or DispersinB treatment (Fig 4C).
Equine and porcine ex vivo models of human synovial fluid biofilms
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TPA disperses Staphylococcal and non-Staphylococcal biofilm aggregates
and restores antimicrobial activity in synovial fluid from multiple species
Because TPA most effectively dispersed S. aureus biofilm aggregates in equine synovial fluid
(Fig 4A and 4B), we determined if it would also disperse S. aureus biofilm aggregates in
human and porcine synovial fluid. We found that TPA was able to visibly disperse aggregates
in equine, human, and porcine synovial fluid (p<0.0002; Fig 5A) and that dispersal was able to
restore the antimicrobial activity of amikacin against S. aureus at 10× MIC (p<0.0004; Fig 5B).
In addition, we showed that TPA could disperse aggregates of the equine clinical isolates (S.
aureus, S. zooepidemicus, E. coli and P. aeruginosa) (Fig 6A), with restoration of antimicrobial
activity against both gram-positive and gram-negative bacteria cultured in equine synovial
fluid (p<0.001; Fig 6B).
Fig 4. Enzymatic dispersal of synovial fluid biofilm aggregates restores antimicrobial efficacy. (A) S. aureus
(ATCC25923) biofilm aggregates in equine synovial fluid were treated with several enzymes in an attempt to
breakdown the extracellular matrix and disperse the bacteria: hyaluronidase (1mg/mL), proteinaseK (200μg/mL),
trypsin (200μg/mL), endopeptidase or LysC (200μg/mL), DNase (500μg/mL), collagenase type II (750μg/mL),
collagenase type IV (750μg/mL), dispase (500μg/mL), DispersinB (1mg/mL), acetylcysteine (8mg/mL) and tissue
plasminogen activator or TPA (1mg/mL). Synovial fluid containing biofilm aggregates was treated with the respective
enzyme for 1 hour prior to macroscopic imaging. (B) Percent (%) dispersal was evaluated by measuring absorbance
(600nm) and calculating a percentage compared to planktonic S. aureus grown in TSB to a similar CFU/mL. (C) After
1 hour of dispersion, amikacin was added at 10× MIC (40μg/mL) and log CFU/mL was measured with serial dilutions
and colony counting 8 hours post-antimicrobial challenge. Bars are means and standard deviations of four biological
replicates (n = 4), and significant differences (p<0.05) as determined by ANOVA with Tukey post-hoc are indicated
by differing letters.
https://doi.org/10.1371/journal.pone.0221012.g004
Equine and porcine ex vivo models of human synovial fluid biofilms
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Discussion
The purpose of this study was to examine the ability of S. aureus, the most commonly isolated
bacteria from cases of infectious arthritis and periprosthetic joint infection[2,4–7], as well as
non-Staphylococcal species, to aggregate and form free-floating biofilms in equine and porcine
synovial fluid, a characteristic of infected human synovial fluid. We provide compelling evi-
dence that biofilm aggregates are similar in structure and function across species indicating
that both equine and porcine synovial fluid can be used as ex vivo model systems of human
joint infection.
Biofilm aggregate formation in synovial fluid offers protection from traditional antimicro-
bial therapies[17,19] and the host immune system[47–49]. The results presented here show
that antimicrobials can be used at 100× MIC in synovial fluid with little to no killing activity in
vitro, while planktonic cells are easily killed at the same MIC. Based on the wildtype MIC of
4μg/mL used in this study, the clinical breakpoint for susceptible isolates of S. aureus, S. zooepi-
demicus, E. coli, and P. aeruginosa, and pharmacokinetic studies in horses[50], the aminogly-
coside amikacin can achieve a concentration of ~5× MIC in synovial fluid after intravenous
administration of a clinically relevant 10mg/kg dose. However, unlike systemic administration,
local administration of amikacin to horses by regional limb perfusion or direct intra-articular
injection can achieve a concentration in synovial fluid up to 100× MIC[51–53]. Conversely,
local administration of amikacin to inflamed joints decreases the maximal concentration to
~50× MIC[52]. Therefore, concentrations between 1× to 100× MIC are considered within
pharmacodynamic range of amikacin. Nevertheless, our studies show that we could not
achieve a significant antibacterial effect even at 100× MIC of amikacin against bacteria cul-
tured in synovial fluid due to their aggregation. These results indicate that clinical dosing of
amikacin would be ineffective against biofilm aggregates in synovial fluid, which offers a
Fig 5. Tissue plasminogen activator (TPA) disperses S. aureus biofilm aggregates and restores antimicrobial
activity in equine, human and porcine synovial fluid. (A) Equine, human and porcine synovial fluid containing S.
aureus (ATCC25923) biofilm aggregates was left untreated or treated with DispersinB (1mg/mL) or TPA (1mg/mL)
for 1 hour prior to macroscopic imaging. (B) Percent (%) dispersal was evaluated by measuring absorbance (600nm)
and calculating a percentage compared to tryptic soy broth (TSB) containing planktonic S. aureus at a similar CFU/
mL. (C) After 1 hour of dispersion, amikacin was added at 10× MIC (40μg/mL) and log CFU/mL was measured with
serial dilutions and colony counting 8 hours post-antimicrobial challenge. Bars are means and standard deviations of
four biological replicates (n = 4), and significant differences (p<0.05) as determined by ANOVA with Tukey post-hoc
are indicated by differing letters.
https://doi.org/10.1371/journal.pone.0221012.g005
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possible explanation for persistent sepsis and increased severity of degenerative joint disease
following infectious arthritis[54,55].
The antimicrobial tolerance displayed by bacteria in synovial fluid is similar to surface-
attached biofilms and other biofilm aggregates such as those of P. aeruginosa in the sputum of
CF patients[13,23,24]. In vitro models of P. aeruginosa aggregation in synthetic sputum or on
alginate beads imparts significant antimicrobial tolerance[56–59], similar to that observed in
this in vitro infectious arthritis model.
New methods to evaluate the pharmacodynamics of antimicrobial agents within biofilms
are being developed[24,45]. One such method is called a minimum biofilm eradication con-
centration (MBEC), which is the biofilm equivalent to a planktonic minimum bactericidal
concentration (MBC)[60]. The S. aureus MBC for aminoglycosides is within 1× to 4× MIC
whereas the MBEC for aminoglycosides can reach concentrations greater than 1000× the
MIC/MBC[61–63]. The MIC and MBC for amikacin can be achieved using clinical doses;
however, the MBEC concentration is not within the therapeutic index of aminoglycosides. For
example, concentrations higher than those currently achieved by local administration of ami-
kacin are toxic to the articular cartilage and can cause nephrotoxicity or ototoxicity by systemic
administration[64,65]. These observations correlate with pharmacokinetic studies reporting
that MBECs are typically not achievable using clinical doses within the planktonic therapeutic
index[66–68]. Therefore, new methods that combine tissue location-specific pharmacokinetic
data and biofilm-specific pharmacodynamic data are vital to improve the clinical treatment of
biofilm infections. The methods developed in this study could serve as a platform with
Fig 6. TPA disperses synovial fluid biofilm aggregates and restores antimicrobial activity against both gram-
negative and gram-positive aggregates. (A) The four arthrotropic bacterial isolates from Fig 2 were grown in equine
synovial fluid. Synovial fluid containing these aggregates bacteria was treated with TPA (1mg/mL) for 1 hour prior to
macroscopic imaging. B) Percent (%) dispersal was evaluated by measuring absorbance (600nm) and calculating a
percentage compared to planktonic S. aureus grown in TSB to a similar CFU/mL. (C) After 1 hour of dispersion,
amikacin was added at 10× MIC (40μg/mL) to the infected synovial fluid containing biofilm aggregates and log CFU/
mL was measured with serial dilutions and colony counting 8 hours post-antimicrobial challenge. Bars are means and
standard deviations of four biological replicates (n = 4), and significant differences (p<0.05) as determined by
ANOVA with Tukey post-hoc are indicated by differing letters.
https://doi.org/10.1371/journal.pone.0221012.g006
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improved translational fidelity to generate in vitro pharmacodynamics data within the articu-
lar-specific location.
In this study, we show dispersal of synovial fluid biofilm aggregates restores antimicrobial
activity. This is similar to other reports of restoration of antimicrobial activity after dispersing
surface-attached biofilms in vitro and in vivo[18,44–46]. Most biofilm in vitro studies rely
heavily on traditional microbiological media, such as tryptic soy broth (TSB), which yields a
biofilm matrix composed of bacterial-derived polysaccharide intercellular adhesion (PIA)[69–
71]. In that regard, DispersinB, an enzyme that specifically targets PIA, has the ability to dis-
perse S. aureus biofilms formed in vitro by traditional methods, whereas proteinaseK is unable
to do so[72]. In contrast, this report shows that the biofilm aggregate matrix generated in syno-
vial fluid is predominantly composed of proteins; therefore, treatment with proteinaseK,
among other enzymes with proteolytic activity, but not DispersinB, dispersed aggregates.
These results line up with previous work that reported PIA-independent biofilm aggregate for-
mation in synovial fluid and dispersal with proteinaseK[17,43] In addition, other studies have
noted that in vivo biofilms and biofilm aggregates tend to be embedded in a host-derived extra-
cellular matrix versus a bacterial self-produced matrix such as PIA[12]. S. aureus in particular
has several mechanisms to hijack host fibrinogen[48,73]. Since TPA was able to disperse syno-
vial fluid biofilm aggregates, further investigation into the role of fibrinogen as an extracellular
matrix component is warranted. Due to the ability of dispersion to restore antimicrobial activ-
ity, dispersal agents could decrease the MBEC of biofilm aggregates to fall within the therapeu-
tic index of clinically relevant antimicrobial agents. This is a promising area of future study.
Human synovial fluid, particularly non-diseased, is difficult to obtain and identification of
an alternative model that allows for movement between in vitro and in vivo components is crit-
ically needed to advance the field of biofilm aggregate research. Our findings show that both
equine and porcine synovial fluid allow for robust biofilm aggregate formation with similar
phenotypes to biofilm aggregates formed in human synovial fluid. Noteworthy, although
rodent and rabbit models have been used extensively in infectious arthritis and PJI in vivo
research[25,26,74], it is impractical to use these species for the ex vivo studies we have
described here. The volume of synovial fluid able to be obtained from rodents is very small,
ranging from 1–5μL per tibiofemoral joint in the mouse[32] up to 10–100μL per tibiofemoral
joint in the rat[31], and 100–400μL per tibiofemoral joint in the rabbit[75]. Horses and pigs
offer a distinct advantage in this regard since volumes of both normal and diseased synovial
fluid range from 1.5-3mL per tibiofemoral joint in the pig [76] to 10-12mL per tibiotarsal joint
in the horse[77]. In addition to these volume differences of up to four orders of magnitude, the
cartilage biology of horses and pigs is very similar to humans[28,33,36–38]. Moreover, these
animals are well supported by the FDA as pre-clinical models for osteoarthritis. Lastly, horses
suffer from naturally occurring infectious arthritis that requires clinical treatment and rehabil-
itation protocols similar to that of humans [42,78,79]. Thus, the horse provides an ideal pre-
clinical and clinical model for translational research.
This study offers a powerful alternative to traditional in vitro biofilm models to specifically
study free-floating biofilm aggregates in physiological fluid. The complexity of host-derived
fluids may influence the bacterial phenotype differently than traditional in vitro media such as
TSB. Therefore, studying bacteria within the context of the infective environment, such as
synovial fluid for infectious arthritis or sputum for cystic fibrosis, has the advantage of explor-
ing the bacteria phenotype similar to what is encountered in vivo. By utilizing the microenvi-
ronment that bacteria encounter upon infection in vivo, the robust ex vivo model system
described in this study offers an important advancement in benchtop biofilm research.
Although the limitation of an ex vivo study is the lack of pressure from the host immune sys-
tem or changes that occur within the biofluid during in vivo infection, such studies are
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imperative prior to performing costly long-term in vivo studies. By utilizing the equine and
porcine model systems described here, we can study the mechanisms by which bacteria form
biofilm aggregates in synovial fluid and become tolerant to antimicrobials. The findings from
these in vitro studies demonstrate a higher degree of model fidelity as the research efforts tran-
sition from in vitro to in vivo model systems. Taken together, we hope that our investigations
help advance new therapeutic modalities with the potential to decrease morbidity and mortal-
ity associated with infectious arthritis and periprosthetic joint infections.
Methods
Bacterial strains
The bacterial strains used in this study were clinical isolates derived from cases of equine septic
arthritis collected by the Pennsylvania Animal Diagnostic Laboratory System (PADLS) New
Bolton Center Clinical Microbiology Laboratory (S. aureus, S. zooepidemicus, E. coli and P. aer-
uginosa). In vitro antimicrobial susceptibility testing and microbial identification was per-
formed using the Sensititre Complete Automated AST System and the equine (Equine
EQUIN1F Vet AST Plate) antimicrobial susceptibility panel (Thermo Fisher Scientific, Wal-
tham, MA). Breakpoint-associated minimum inhibitory concentrations (MIC) of each strain
are presented in Table 1. Where indicated the laboratory strain of S. aureus, ATCC25923, was
used as a well-characterized control strain. Antimicrobial susceptibility of this strain was deter-
mined as described for the clinical isolates. Bacteria were kept in frozen stocks on glycerol at
-80˚C. Blood agar plates were streaked from frozen stocks and used for in vitro experiments
for a maximum of 1 week. Overnight cultures were made from the blood agar plates by taking
one colony and adding to 30mL of tryptic soy broth (TSB); these cultures were made fresh for
each experiment. On the day of an experiment, 100μL of an overnight culture was inoculated
into 10mL of fresh TSB and grown to 0.5 McFarland (~3 hours) to ensure the bacteria were in
the exponential phase of growth. Concentrations of cultures were confirmed using serial plate
dilutions.
Synovial fluid collection
This study was approved by the Institutional Animal Care and Use Committees of The Univer-
sity of Pennsylvania and the North Carolina State University. Healthy horses free of orthopedic
disease and free of medication for 48 hours prior to sampling were used for collection of syno-
vial fluid. Synovial fluid samples were obtained from standing horses sedated with 0.005–0.01
mg/kg detomidine. All horses were well acclimated to standing under sedation for arthrocent-
esis, which is a short procedure. Both carpi were clipped and aseptically prepped along the dor-
sal aspect of the joints and 3–4 mL of synovial fluid was extracted from each joint. Following
synovial fluid collection, 250mg of amikacin was injected into the joint through the same nee-
dle as a preventative measure, as is routinely performed in the clinical setting. Horses were
monitored during the procedure and every 12 hours thereafter for 48 hours for signs of dis-
comfort, pain/lameness, swelling at the site of collection, or other adverse effects, none of
which were observed. Synovial fluid from both the right and left carpi were pooled among
individual horses. Synovial fluid from pigs was collected post-mortem from healthy Yorkshires
~6 months of age. Pigs were part of an unrelated research study of an independent principal
investigator at North Carolina State University and were euthanized with 60 mg/kg iv pento-
barbital sodium following intramuscular sedation using xylazine (2mg/kg) and ketamine (20
mg/kg) and isofluorane until unconsciousness. Death was confirmed via auscultation. Human
synovial fluid was purchased from Lee Biosolutions, Inc. (Maryland Heights, MO). Synovial
fluid that was visually cloudy or otherwise abnormal was discarded. Synovial fluid was
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centrifuged at 1500g for 15 minutes to remove the cellular component and passed through a
40μM cell strainer to remove any large protein aggregates. The samples were stored at -20˚C
until use in the described experiments. All experiments were performed with four biological
replicates (i.e. synovial fluid from four individual horses, humans or pigs).
Synovial fluid biofilm aggregates and planktonic growth conditions
Planktonic bacteria were grown in tryptic soy broth (TSB). Biofilm aggregates were grown in
synovial fluid from the indicated mammalian species. All growth conditions were inoculated
with 1x106 CFU/mL[17] of each bacterial strain in a microtiter plate (24-well or 6-well with
500μL or 2mL of media respectively) and incubated overnight (16–18 hours) in a microaero-
philic chamber (AnaeroPack-MicroAero Gas Generator, Thermo Fisher Scientific, Waltham,
MA) on a shaker at 120rpm at 37˚C. Antimicrobial treatments and dispersal treatments were
implemented during mid to late exponential phase or 6 hours post-infection (S4 Fig) and
added to TSB or synovial fluid containing planktonic or biofilm aggregated bacteria respec-
tively. Macroscopic images were taken with a Nikon D40 camera.
Confocal microscopy
Bacteria were stained with BacLight Green (Thermo Fisher Scientific, Waltham, MA) prior to
inoculation of synovial fluid; after overnight culture in synovial fluid, macroscopic aggregates
were gently removed from synovial fluid and washed three times with phosphate buffered
saline (PBS). Aggregates were suspended in PBS and stained with wheat germ agglutinin
(WGA, Thermo Fisher Scientific, Waltham, MA; 20μg/mL) for 15 min at room temperature in
the dark. Supernatant containing WGA was removed and aggregates were stained with 1mL
undiluted SYPRO (FilmTracer SYPRO Ruby Biofilm Matrix Stain, Thermo Fisher Scientific,
Waltham, MA) for 30 min at room temperature in the dark. Thereafter, stain was removed
and aggregates were washed three times with PBS before fixation in 2% paraformaldehyde.
Aggregates were kept at 4˚C until imaging. Imaging was performed using a Leica SP5 Confo-
cal/Multiphoton Microscope at the PennVet Imaging Core.
Scanning electron microscopy (SEM)
Scanning electron microscopy images were attained by the staff at the Electron Microscopy
Resource Laboratory (EMRL) at the University of Pennsylvania. In brief, aggregates were
washed, fixed in glutaraldehyde, dehydrated, gold sputter coated and subsequently imaged
with a scanning electron microscope at 3000x with a FEI-Tecnai T12 microscope at the
PennMed Imaging Core.
Antimicrobial treatment
Results from the phenotypic susceptibility testing (Table 1) were used to estimate the MIC (μg/
mL) by microbroth dilution of planktonic cultures using the Sensititre Complete Automated
AST System and the equine (Equine EQUIN1F Vet AST Plate) antimicrobial susceptibility
panel. The vancomycin MIC for S. aureus (ATCC25923) was 0.5μg/mL as determined by
microbroth dilution following CLSI standards. Microtiter wells containing infected synovial
fluid (biofilm aggregates) or TSB (planktonic) were treated with antimicrobials at 1×, 10× or
100× the reported MIC of each individual planktonic bacteria during mid to late exponential
phase or 6 hours post-infection (S4 Fig). If an MIC was determined to be less than the lowest
concentration evaluated, that evaluated concentration was used. For example, the MIC of
Amikacin for S. aureus (ATCC25923) was� 4μg/mL; therefore, bacteria was treated with
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amikacin at 4μg/mL for 1×MIC, 40μg/mL for 10×MIC, and 400μg/mL for 100×MIC. Antimi-
crobial treatments were carried out for 8 or 24 hours where indicated under the same growth
conditions as the infective period. The infected TSB or synovial fluid was centrifuged at 8000g
for 10 min and the supernatant was removed. The bacterial pellet was washed 3x with PBS and
resuspended in 1mL of PBS containing 200μg/mL proteinaseK and incubated for 5–10 min-
utes on a shaker at 120rpm at 37˚C to disperse the aggregates for enumeration of bacterial con-
centration by serial dilutions and plate counting of colony forming units (CFU/mL). This
wash and proteinaseK step is critical for appropriate enumeration of bacteria as CFU/mL due
to the inability to measure bacterial concentration within the biofilm aggregates. Dastgheyb
et al. 2015 first showed the inaccuracy of measuring CFU/mL from intact aggregates and
described the ability of proteinaseK to disperse aggregates for accurate enumeration of CFU/
mL[17].
Dispersal treatment
ProteinaseK (200μg/mL), trypsin (200μg/mL), endopeptidase (200μg/mL), DNase (500μg/mL)
collagenase type II (750μg/mL), collagenase type IV (750μg/mL), dispase (500μg/mL), Disper-
sinB (100μg/mL), acetylcysteine (8mg/mL), and tissue plasminogen activator or TPA (1mg/
mL) were used to test dispersal of biofilm aggregates. All enzymes were purchased from
Sigma-Aldrich (St. Louis, MO) apart from DispersinB which was purchased from Kane Bio-
tech (Winnipeg, Canada).The concentration of each enzyme was chosen as the highest con-
centration that did not exhibit bactericidal effects against planktonic bacteria grown in TSB.
Each enzyme was incubated in the infected synovial fluid for 1 hour on a shaker at 120rpm at
37˚C. Photographs of the dispersal treatment were taken with a Nikon D40 camera. Dispersal
was evaluated by measuring optical density (OD) on a microtiter plate reader (Synergy 2, Bio-
Tek Instruments, Inc., Winooski, VT). Optical density was measured as an average of the
absorbance (600nm) using a well-mode, or area scanning, method to ensure the entire well
was measured. Dispersal was reported as a percentage compared to planktonic bacteria (each
bacterial strain was used as its own internal control) in TSB at the same CFU/mL. Specifically,
percentage dispersal was calculated as [(OD infected synovial fluid–OD uninfected synovial
fluid)/(OD infected TSB–OD uninfected TSB)] X 100. This method was developed based on
measurements and calculations of platelet aggregation[80–82]. Bacterial viability (CFU/mL)
was measured post-dispersal and compared to the no treatment control to ensure that enzy-
matic treatment did not induce cell death. After 1 hour of dispersal, enzymatically treated
synovial fluid samples containing biofilm aggregates were challenged with amikacin at 10×
MIC for 8 hours. Bacterial viability (CFU/mL) was assessed post-dispersal and antimicrobial
challenge using serial dilutions and colony counting as described above.
Statistics
Data was analyzed using 1-way non-parametric (Kruskal-Wallis Test) or 1-way/2-way ANOVA
where applicable with Tukey’s post hoc tests. Correlations were calculated using Spearman cor-
relation coefficient. Analysis was performed using JMP Pro 11.0 software (SAS Institute Inc.,
Cary, NC). All graphs were generated using GraphPad Prism (GraphPad Software Inc., La Jolla
California USA). For all comparisons, p<0.05 was considered statistically significant.
Supporting information
S1 Fig. Time dependent growth and biofilm aggregate formation in equine synovial fluid.
Equine synovial fluid was infected at 1x106 CFU/mL with S. aureus (ATCC25923) and incu-
bated overnight at 37˚C in a microaerophilic chamber on a shaker at 120rpm to mimic the
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joint environment. (A) S. aureus growth in synovial fluid over time was measured by treating
synovial fluid with proteinaseK (20μg/mL) to disperse aggregates, followed by serial dilutions
and plate counting for CFU/mL. (B) Biofilm aggregate formation was photographed at the
same time as bacterial load determination.
(TIF)
S2 Fig. Planktonic bacteria are inhibited or killed by several different classes of antimicro-
bials. S. aureus (ATCC25923) was grown planktonically in TSB for 6 hours and challenged
with a panel of different antimicrobials from several drug classes at 100× the minimum inhibi-
tory concentration (MIC) as determined by in vitro antimicrobial susceptibility testing
(Table 1).
(TIF)
S3 Fig. Hyaluronidase pre-treatment but not post-treatment of synovial fluid prevents bio-
film aggregate formation and development of antimicrobial tolerance. (A) Equine synovial
fluid was either left untreated or pre-treated with hyaluronidase (1mg/mL) prior to infection
with S. aureus (ATCC25923). Bacteria were added, incubated for 16 hours and either left
untreated or post-treated with hyaluronidase (1mg/mL) for 1 hour. Thereafter, amikacin was
added at 10× MIC (40μg/mL), incubated for 8 hours, and log CFU/mL was measured with
serial dilutions and colony counting. Bars are means and standard deviations of four biological
replicates (n = 4), and significant differences (p<0.05) as determined by ANOVA with Tukey
post-hoc are indicated by differing letters.
(TIF)
S4 Fig. Enzymatic treatment of synovial fluid containing biofilm aggregates does not alter
bacterial load >1 log CFU/mL. Equine synovial fluid containing S. aureus (ATCC25923) bio-
film aggregates were treated with: hyaluronidase (1mg/mL), proteinaseK (200μg/mL), trypsin
(200μg/mL), endopeptidase or LysC (200μg/mL), DNase (500μg/mL), collagenase type II
(750μg/mL), collagenase type IV (750μg/mL), dispase (500μg/mL), DispersinB (1mg/mL),
acetylcysteine (8mg/mL) or tissue plasminogen activator or TPA (1mg/mL). Bacterial load
(log CFU/mL) was measured with serial dilutions and colony counting 9 hours post-enzymatic
treatment. Bars are means and standard deviations of four biological replicates (n = 4), and sig-
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